NCT02973503View on ClinicalTrials.gov

Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis

PHASE3CompletedINTERVENTIONAL

Enrollment

117

Participants

Timeline

Start Date

January 11, 2017

Primary Completion Date

November 10, 2018

Study Completion Date

April 30, 2019

Conditions

Chronic HCV Infection

Interventions

DRUG

Elbasvir/Grazoprevir Fixed Dose Combination

Evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).

Trial Locations (1)

63003

CHU Clermont-Ferrand, Clermont-Ferrand

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University Hospital, Clermont-Ferrand

OTHER

NCT02973503 - Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis | Biotech Hunter | Biotech Hunter